. Author manuscript; available in PMC: 2013 Jul 10.

Published in final edited form as: Ann Pharmacother. 2013 Jun 18;47(0):984–992. doi: 10.1345/aph.1S050

Table 3.

Effect of the Release of the NCEP ATP III Guidelines and Results from PROSPER Study in 2002 on Cholesterol-Lowering Medications Use^a

Drug Class	Level Changes		Trend Changes

	Observed vs. Predicted (using pre-guideline trend) Difference in Use in year 2003 (Adjusted OR, 95% CI) ^a	P-value	Pre-Guideline Trend per year (Adjusted OR and 95% CI) ^a	Post-Guideline Trend per year (Adjusted OR and 95% CI) ^a	Post-vs. Pre-Guideline Difference in Trends Over Time per year (Adjusted ROR, 95% CI) ^a	p-value
Any Cholesterol Lowering Medication Use	0.95 (0.89, 1.02)	0.18	1.18 (1.15, 1.20)	1.09 (1.02, 1.15)	0.92 (0.89, 0.95)	<0.0001
Any Statin Use	0.95 (0.88, 1.01)	0.12	1.19 (1.16, 1.22)	1.07 (1.01, 1.13)	0.90 (0.87, 0.93)	<0.0001
Any Fibrate/Other Use	1.04 (0.83, 1.30)	0.74	1.02 (0.93, 1.08)	1.24 (1.01, 1.46)	1.22 (1.10, 1.35)	0.0003

Multivariate generalized estimating equations models adjusted for sociodemographics (race, age, sex, site, education, living status), health behavior (alcohol use), and health status (pulmonary disease, body mass index, polypharmacy, and prescription medications coverage). Polypharmacy and prescription coverage are time-varying variables.

Abbreviation: CI: confidence interval; OR: odds ratio; ROR: ratio of odds ratio